Table of Contents
ISRN Rheumatology
Volume 2014 (2014), Article ID 354648, 3 pages
Research Article

Minimally Invasive Minor Salivary Gland Biopsy for the Diagnosis of Amyloidosis in a Rheumatology Clinic

1Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ic Hastalıklari ABD, Romatoloji BD, Besevler, 06500 Ankara, Turkey
2Department of Rheumatology, Kartal Research and Training Hospital, 34890 Istanbul, Turkey
3Department of Rheumatology, State Hospital, 20125 Denizli, Turkey

Received 19 December 2013; Accepted 15 January 2014; Published 23 February 2014

Academic Editors: S. Coaccioli and T. Miyazaki

Copyright © 2014 Ridvan Mercan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Systemic amyloidosis is a potentially fatal condition, unless diagnosed and treated before development of irreversible organ damage. Demonstration of amyloid deposits within tissue biopsies is only definitive diagnostic method, which makes appropriate selection of biopsy site essential. Herein, we evaluated efficacy of minimally invasive minor salivary gland biopsy (MSGB) for the diagnosis of amyloidosis. Methods. We analyzed 37 biopsies taken from 35 patients. Suggestive findings for amyloidosis were significant proteinuria, renal impairment, refractory diarrhea, neuropathy, and restrictive cardiomyopathy. Minor salivary gland was the initial biopsy site in all subjects. When MSGB was negative but there was a high suspicion for amyloidosis, a kidney, duodenum, or rectal biopsy was performed for further investigation. Results. Mean age of patients was 45.4 and 21 were female. In 11 patients amyloidosis was diagnosed with MSGB. In overall 18 patients were diagnosed with amyloidosis. Sixteen of them were identified as being of AA type and two were AL type amyloidosis. The sensitivity of minimally invasive MSGB is 61.1% for diagnosing amyloidosis in this study. Conclusion. MSGB is a safe and simple method for the diagnosis of amyloidosis which can be performed in an outpatient setting. We suggest extensive use of this minimally invasive method.